Cyclacel Pharma (CYCC) Misses Q4 EPS by 45c

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($1.18), $0.45 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $277 thousand versus the consensus estimate of $210 thousand.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Worthington Industries (WOR) Misses Q4 EPS by 9c